Form D · Other
DX Biosciences, Inc.
San Diego, CA · CIK 0001504072
Offering snapshot reported Mar 7, 2013 · SEC filing
- Reported sold
- $529K Offering amount: $1.59M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 25, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 7, 2013 | Initial | $529,386 | No comparison | 6 | SEC filing |
| Nov 16, 2010 | Initial | $300,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-192862
Source: Form D, filed Mar 7, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sallie Cassel | Executive |
| Sallie Cassel | Executive |
| Frank Foster | Director |
| Daniel Haimovic | Director |
| Daniel Haimovic | Director |
| My Phuong Lam | Executive |
| Robert Langer | Director |
| Russell Lebovitz | Director, Executive |
| Samir Mitragotri | Director |
| Dan Watkins | Director |
Issuer details
Industry: Other (See others in industry)
Address:
10620 Treena Street Suite 230
San Diego, CA, 92131
San Diego, CA, 92131